Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection

Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.) has received final approval from the United States Food and Drug Administration (USFDA) to market Pemetrexed for Injection, in the strengths of 100 mg/vial,500 mg/vial, and 1000 mg/vial Single-Dose Vials (USRLD: Alimta). Pemetrexed is used to treat certain types of cancers such as lung cancer, mesothelioma. It is a chemotherapy drug that works by slowing or stopping the growth of cancer cells. The drug will be manufactured at Zydus Hospira. Pemetrexed for Injection has a market size of USD 1,236 mn (as per IQVIA MAT March'22).

The group now has 314 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 372.85 as compared to the previous close of Rs. 366.25. The total number of shares traded during the day was 66872 in over 1908 trades.

The stock hit an intraday high of Rs. 374.00 and intraday low of 363.80. The net turnover during the day was Rs. 24671697.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 FinalApproval USFDA Pemetrexed Injection